SML3213
Lobaplatin
≥98% (NMR)
别名:
Cis-[trans-1,2-cyclobutanebis(methylamine)-N,N′]-[(2S)-lactate-O1,O2)-platinum (II), D 19466, D-19466, D19466, [rel-(1R,2R)-1,2-cyclobutanedimethanamine-κN,kN′][(2S)-2-(hydroxy-kO)propanoato(2-)-kO]-, (SP-4-3)-platinum, trans-1,2-Cyclobutanedimethanamine, platinum complex
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Quality Level
assay
≥98% (NMR)
form
powder
color
white to beige
solubility
H2O: 2 mg/mL, clear (Warmed)
storage temp.
−20°C
SMILES string
O=C1[O-][Pt+2]2(N[CH2]C3CCC3CN2)[O-]C1C
InChI
1S/C6H12N2.C3H5O3.Pt/c7-3-5-1-2-6(5)4-8;1-2(4)3(5)6;/h5-8H,1-4H2;2H,1H3,(H,5,6);/q-2;-1;+4/p-1/t;2-;/m.0./s1
InChI key
HADHSETVEMCBPU-TYOUJGAFSA-M
Biochem/physiol Actions
Lobaplatin (D-19466) is a third-generation platinum anticancer agent in vitro and in vivo, consisting of ~50:50 mixture of the two trans-1,2-cyclobutanedimethanamine diastereomers in complex with L-lactic acid. Llobaplatin shows antitumor efficacy against various human cancer cancer xenografts and significantly prolongs the survival of mice bearing P388 leukemia (mean life span increase post single i.p. in mg/kg = 46%/4.64 & 77/14.7). Compared to first and second generation platinum compounds, lobaplatin appears to be more stable, less toxic, have a better therapeutic index and may overcome tumor resistance.
Third-generation platinum anticancer agent in vitro and in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Lina Shan et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 108, 486-491 (2018-09-23)
Peritoneal metastasis from colorectal cancer (CRC) is related to poor prognosis. Intraperitoneal chemotherapy is an efficient method to treat peritoneal metastasis (PM); however, the outcomes remain unsatisfactory. The present study aimed to investigate the antitumor activity of lobaplatin and its
Dong Li et al.
Cell death & disease, 10(10), 744-744 (2019-10-05)
We investigated the mechanism underlying the effect of a combination treatment of 125I radioactive seed implantation and lobaplatin (LBP) in hepatocellular carcinoma. The effects of administration of HCC cells and subcutaneous tumor model of mice with different doses of 125I
R Voegeli et al.
Journal of cancer research and clinical oncology, 116(5), 439-442 (1990-01-01)
D-19466, a new platinum complex, was characterized. It showed no nephrotoxic side-effects as determined by the measurement of blood urea. It was cytotoxic in vitro for tumor cells in concentrations comparable to or lower than cytotoxic concentrations of cisplatin. It
A Harstrick et al.
Cancer chemotherapy and pharmacology, 33(1), 43-47 (1993-01-01)
Lobaplatin [1,2-diamminomethylcyclobutane-platinum(II) lactate] is a new platinum compound with interesting preclinical activity and apparently no nephro- or neurotoxicity that is currently undergoing clinical phase II studies. Little is known about the cross-resistance between cisplatin and lobaplatin. The activity of this
Shupei Pan et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 102, 567-574 (2018-03-30)
Radiotherapy is one of the common treatments for esophageal squamous cell carcinoma (ESCC). Yet, local recurrence led by radioresistance is still not solved. Lobaplatin (LBP) is known to have powerful clinical anti-tumor activities in various tumors, but its effect in
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML3213-5MG | 04065267369006 |
| SML3213-25MG | 04065267368993 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持